Le Lézard
Classified in: Ebola virus, Health
Subject: ACC

Meda Aktiebolag Successfully Amends MTN Terms and Conditions and Exercises Call Option

SOLNA, Sweden, Dec. 6, 2017 /PRNewswire/ --

Meda Aktiebolag has successfully amended the terms and conditions of two series of notes issued pursuant to its SEK 7,000,000,000 medium term notes programme and inserted an early redemption call option which it will exercise with immediate effect

Today, Meda Aktiebolag (the "Company") held two noteholders' meetings pursuant to the summons sent on 7 November 2017 to the noteholders of the:

(i) SE0005132180 ? STIBOR 3M +2.85% 2013/2018 notes (the "2018 Notes"); and

(ii) SE0005991635 ? STIBOR 3M +1.65% 2014/2019 notes (the "2019 Notes" and together, with the 2018 Notes, the "Notes"),

issued under the SEK 7,000,000,000 medium term notes programme of the Company originally established on 25 May 2012 (as updated on 31 July 2012, 12 May 2014 and 16 July 2015), for the purposes of approving an amendment to the terms and conditions of the Notes to insert an early redemption call option (the "Call Option").

A sufficient number of noteholders were present in order for each noteholders' meeting to be quorate and a requisite majority of the voting noteholders at each noteholders meeting voted in favour of approving the proposed amendment to the terms and conditions.

As at the date hereof, the terms and conditions of the Notes have been effectively amended and the Company has given notice to the noteholders of each series of Notes that it will exercise the Call Option in accordance with the amended terms and conditions.

For further information regarding the amended terms and conditions and the Call Option, please refer to Skandinaviska Enskilda Banken AB (publ) acting as Tabulation and Paying Agent.

The Tabulation and Paying Agent:


Skandinaviska Enskilda Banken AB (publ)
Stjärntorget 4
SE-106 40 Stockholm
Tel: +46 (0)8 763 80 96
Email: sebtenderagent@seb.se
Attention: SEB Tender Agent


The Board of directors
Meda Aktiebolag

For further inquiries, please contact:

Melissa Trombetta,
Head of Global Investor Relations
Mylan NV.
Tel: +1(917)262-2958

This is information that Meda Aktiebolag is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 12:45 noon CET on 6 December 2017.

Meda Aktiebolag is a leading international specialty pharma company. Meda's products are sold in more than 120 countries worldwide and the company is represented by its own organizations in close to 60 countries. Find out more, visit www.meda.se.

This information was brought to you by Cision http://news.cision.com

The following files are available for download:


Press release (PDF)



These press releases may also interest you

21 fév 2018
The Annual General Meeting of shareholders of Telefonaktiebolaget LM Ericsson will be held on Wednesday, March 28, 2018, at 3 p.m. at Kistamässan, Arne Beurlings Torg 5, Kista/Stockholm. The Nomination Committee proposes among other things: Ronnie...

21 fév 2018
NanoViricides, Inc. (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), filed its quarterly report for its second quarter of financial year 2018 in a...

19 fév 2018
Though not likely to immediately realize the billion-dollar revenues projected in many sources, molecular point-of-care is here to say, says market researcher Kalorama Information.  The molecular point-of-care market, consisting of systems with...

15 fév 2018
A Notice is given to the Shareholders of Svenska Cellulosa Aktiebolaget SCA ("SCA") of the Annual General Meeting of Shareholders to be held on Friday 23 March 2018, at 10.30 a.m. at Hotell Södra Berget, Sundsvall (registration from 9 a.m.)...

15 fév 2018
Notice is hereby given that the Annual General Meeting of Aktiebolaget SKF will be held at SKF Kristinedal, Byfogdegatan 4, Gothenburg, Sweden, at 13.00 on Tuesday, 27 March 2018. The doors are open from 11.00. Refreshments will be served prior to...

12 fév 2018
Aethlon Medical, Inc. , a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that its CEO, Jim Joyce will give a presentation at the 2018 American Society for Microbiology (ASM) Biothreats Meeting. ...

News published on 6 december 2017 at 07:16 and distributed by: